198 related articles for article (PubMed ID: 22571507)
1. A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children.
Caselli D; Cesaro S; Ziino O; Ragusa P; Pontillo A; Pegoraro A; Santoro N; Zanazzo G; Poggi V; Giacchino M; Livadiotti S; Melchionda F; Chiodi M; Aricò M
Br J Haematol; 2012 Jul; 158(2):249-255. PubMed ID: 22571507
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
3. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
4. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.
Tan BH; Low JG; Chlebicka NL; Kurup A; Cheah FK; Lin RT; Goh YT; Wong GC
Int J Infect Dis; 2011 May; 15(5):e350-6. PubMed ID: 21397541
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
[TBL] [Abstract][Full Text] [Related]
6. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
[TBL] [Abstract][Full Text] [Related]
7. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
9. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.
de Pauw BE; Sable CA; Walsh TJ; Lupinacci RJ; Bourque MR; Wise BA; Nguyen BY; DiNubile MJ; Teppler H
Transpl Infect Dis; 2006 Mar; 8(1):31-7. PubMed ID: 16623818
[TBL] [Abstract][Full Text] [Related]
10. Breakthrough Hormographiella aspergillata infections arising in neutropenic patients treated empirically with caspofungin.
Suarez F; Olivier G; Garcia-Hermoso D; Randriamalala E; Ghez D; Bruneau J; Kauffmann-Lacroix C; Bougnoux ME; Lortholary O
J Clin Microbiol; 2011 Jan; 49(1):461-5. PubMed ID: 21068290
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
J Antimicrob Chemother; 2009 Jun; 63(6):1276-85. PubMed ID: 19346292
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.
Prentice HG; Hann IM; Herbrecht R; Aoun M; Kvaloy S; Catovsky D; Pinkerton CR; Schey SA; Jacobs F; Oakhill A; Stevens RF; Darbyshire PJ; Gibson BE
Br J Haematol; 1997 Sep; 98(3):711-8. PubMed ID: 9332329
[TBL] [Abstract][Full Text] [Related]
13. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment?
Cherif H; Kalin M; Björkholm M
Eur J Haematol; 2006 Oct; 77(4):288-92. PubMed ID: 16856930
[TBL] [Abstract][Full Text] [Related]
14. Caspofungin versus liposomal amphotericin B: are they really comparable?
Sekine L; Humbwavali J; Wolff FH; Barcellos NT
Pediatr Infect Dis J; 2010 Oct; 29(10):985-6; author reply 986-7. PubMed ID: 20859182
[No Abstract] [Full Text] [Related]
15. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.
Schuler U; Bammer S; Aulitzky WE; Binder C; Böhme A; Egerer G; Sandherr M; Schwerdtfeger R; Silling G; Wandt H; Glasmacher A; Ehninger G
Onkologie; 2007 Apr; 30(4):185-91. PubMed ID: 17396041
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial.
Santolaya ME; Alvarez AM; Acuña M; Avilés CL; Salgado C; Tordecilla J; Varas M; Venegas M; Villarroel M; Zubieta M; Farfán M; de la Maza V; Vergara A; Valenzuela R; Torres JP
J Antimicrob Chemother; 2018 Oct; 73(10):2860-2866. PubMed ID: 30010931
[TBL] [Abstract][Full Text] [Related]
20. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; Socié G; Porcher R; Ribaud P; Touratier S; Molina JM
Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]